MiPLA
N-methyl-N-isopropyl-d-lysergamide
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MiPLA (N-methyl-N-isopropyllysergamide) is a semi-synthetic psychedelic of the lysergamide class. It is a structural isomer of LSD — same molecular formula, different carbon arrangement — and approximately one-third to one-half as potent.[1][2] It activates serotonin receptors, disrupting sensory filtering and producing the visual and cognitive shifts characteristic of classical psychedelics.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +3 moreLSD, psilocybin, mescaline, DMT, 2C-B, DOI show less
MiPLA first appeared in a 1956 Eli Lilly patent filed by Richard Pioch,[3] though no pharmacological study followed for nearly forty years. Researchers confirmed its LSD-like activity in animals in 1994,[1] then it appeared on novel psychoactive substance markets around 2019.[4] It now circulates on blotter paper, where its identical molecular weight to LSD creates persistent misidentification problems for drug-checking services.[5]
Subjective effects include euphoria, tactile enhancement, brightened colors, light surface patterning, and stimulation. The experience is body-forward — warm physical engagement with modest visuals and notably less cognitive weight than LSD, closer to a different balance of the same pharmacology than a diluted copy. Anxiety, thought loops, and restlessness are common unsought effects.
MiPLA produces no physical dependence, and no lethal dose has been established — rapid tolerance makes compulsive redosing self-limiting.[6] The primary risk is psychological: panic in uncontrolled settings, compounded by the possibility that blotters sold as LSD may contain MiPLA at different potency.[2] A single 1994 receptor study and scattered forensic analyses constitute the entire evidence base — no clinical trials exist.
History[edit]
Discovery
MiPLA first appeared in US Patent 2,997,470A, filed on March 5, 1956, by Richard Pioch and assigned to Eli Lilly.[3] The patent described synthesis of "lysergic acid N-methyl N-isopropyl amide" alongside related compounds. No pharmacological study followed for nearly forty years.
Pharmacological characterization
In 1994, Huang and colleagues published the first receptor binding and behavioral study of MiPLA.[1] They confirmed it produced LSD-like effects in trained animals at proportionally higher doses. No further pharmacological research has been published since.
Market emergence
MiPLA appeared on novel psychoactive substance markets around 2018–2019, first documented in paper products seized in Japan.[4] Blotters were found to contain approximately 180–186 µg per unit, with laboratory methods developed to differentiate them from LSD.[2] By 2023, a prodrug variant — 1cP-MiPLA — had appeared,[7] and European drug-checking proficiency tests identified MiPLA/LSD confusion as among the most common analytical errors.[5]
The name "MiPLA" derives from its amide substituents: Methyl-isoPropyl Lysergic acid Amide. Several secondary sources attribute the compound to Albert Hofmann at Sandoz, but the relevant Sandoz patent covers compounds at a different structural position. The Pioch/Eli Lilly patent remains the only verified primary source — the misattribution likely reflects confusion between concurrent lysergamide research programs at Sandoz and Eli Lilly in the 1950s.
Chemistry[edit]
Structural class
MiPLA belongs to the lysergamide family — chemical derivatives built on the ergoline ring system, the same rigid four-ring scaffold underlying LSD and other ergot-derived compounds.[8] The amide group at the core carries one methyl and one isopropyl substituent on the amide nitrogen.[9]
Molecular properties
MiPLA and LSD share the same molecular formula (C₂₀H₂₅N₃O, molecular weight 323.4 g/mol) but distribute those atoms differently — making them structural isomers.[2] LSD places two ethyl groups on the amide nitrogen; MiPLA uses one methyl and one larger isopropyl group. The identical molecular weight is why standard laboratory tests cannot reliably distinguish the two compounds.
Pharmacology[edit]
Mechanism of action
MiPLA is a serotonin receptor agonist. The only substance-specific study — conducted by Huang and colleagues in 1994 — confirmed it produces LSD-like effects in trained animals at doses roughly 2–3 times higher than LSD.[1]
By class inference from LSD, MiPLA also likely interacts with dopamine receptors[10][11] and a monoamine-regulating receptor called TAAR₁.[12] No substance-specific data confirm either of these targets.
Pharmacokinetics
No human pharmacokinetic data exist for MiPLA. Community reports describe a substantially shorter total duration than LSD, though what drives this difference — faster receptor dissociation or some other mechanism — remains unknown.[13][14] Metabolism is presumed hepatic by class inference from other lysergamides,[15] but specific enzymes and metabolites have not been identified.
Neuroscience[edit]
Where it acts
No neuroimaging studies have been conducted with MiPLA. As a serotonin receptor agonist that fully substitutes for LSD in behavioral assays,[1] it is expected to disrupt the brain's default mode network — the system that maintains a stable sense of self — and to reduce the brain's filtering of incoming sensory signals, allowing more raw experience through.
Why it matters
A leading model proposes that psychedelics reduce the brain's confidence in its existing predictions, allowing sensory experience to propagate more freely. MiPLA's character — perceptual effects with less cognitive disruption than LSD — may reflect partial engagement: enough to shift how the senses work, without fully destabilizing higher-level thinking.
What accounts for MiPLA's shorter duration compared to LSD — is it faster receptor dissociation, or does the isopropyl group disrupt the binding mechanism that prolongs LSD's effect? Does the shorter exposure translate to weaker neuroplastic signaling?
Subjective Effects[edit]
MiPLA produces a body-forward experience — warm physical engagement, elevated mood, and a sense of tactile aliveness. Colors brighten and surfaces develop light patterning, but visuals stay in the background rather than commanding attention.[13] Set and setting shape the arc strongly.
Within the lysergamide family, MiPLA sits closest to AL-LAD in duration and character — similar recreational feel, but with even less visual intensity and more emphasis on mood and body sensation. Reports consistently describe it as qualitatively distinct from LSD rather than simply weaker.
Effect Grid
At common doses (100–200 µg oral), the full MiPLA experience is established. Visual effects include drifting, color enhancement, symmetrical texture repetition, tracers, and diffraction patterns, though these remain less pronounced than LSD at equivalent subjective intensity. Cognitive euphoria is prominent — thought acceleration, pattern recognition enhancement, and conceptual thinking emerge. The experience is described as "mind-altering in an open, expansive way" with substantially less mental confusion or thought loops than LSD.
Physically, stimulation is moderate, with body load similar to LSD: some cramping, peripheral vasoconstriction, and an "edgy" quality. Enhanced tactile sensations are a distinguishing feature. Total duration is 4–6 hours with peak effects lasting 1–2 hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Geometry · Visual breathing · Tracers · Symmetrical texture repetition · Auditory enhancement · Brightness alteration · Environmental patterning · Light sensitivity · Perspective distortion · Sound sensitivity · Visual morphing · Holotropic state · Depth perception distortion · Auditory distortion · After-images · Touch enhancement · Visual diffraction · Peripheral vision distortion · Proprioceptive distortion · Spatial disorientation · Visual haze / noise · Visual melting · Visual acuity enhancement · Auditory misinterpretation · Peripheral misidentification · Synesthesia · Vestibular distortion · Visual processing acceleration · Flashbacks · Object transformations · Internal hallucinations · Object activation · Visual recursion · External hallucinations · Environmental orbism / cubism · Auditory hallucinations · Perspective hallucinations · Visual scenery slicing · Persisting hallucinations
Auditory enhancement · Brightness alteration · Environmental patterning · Light sensitivity · Perspective distortion · Sound sensitivity · Visual morphing · Holotropic state · Depth perception distortion · Auditory distortion · After-images · Touch enhancement · Visual diffraction · Peripheral vision distortion · Proprioceptive distortion · Spatial disorientation · Visual haze / noise · Visual melting · Visual acuity enhancement · Auditory misinterpretation · Peripheral misidentification · Synesthesia · Vestibular distortion · Visual processing acceleration · Flashbacks · Object transformations · Internal hallucinations · Object activation · Visual recursion · External hallucinations · Environmental orbism / cubism · Auditory hallucinations · Perspective hallucinations · Visual scenery slicing · Persisting hallucinations
Wakefulness · Stimulation · Appetite suppression · Spontaneous body sensations · Body high · Tingling / electric sensations · Tactile euphoria · Muscle tension · Body schema distortion · Dizziness · Heart rate perception changes · Laughter fits · Physical fatigue · Restlessness · Vibrations / buzzing · Nausea · Excessive sweating · Dry mouth · Bodily lightness · Breathing alteration · Involuntary body movements · Sexual arousal enhancement · Bodily heaviness · Headache · Vasoconstriction · Yawning · Salivation · Increased urination · Abnormal heartbeat · Nystagmus (eye wobbles) · Trembling · Motor control enhancement · Vomiting · Seizure threshold reduction · Bodily dissociation
Spontaneous body sensations · Body high · Tingling / electric sensations · Tactile euphoria · Muscle tension · Body schema distortion · Dizziness · Heart rate perception changes · Laughter fits · Physical fatigue · Restlessness · Vibrations / buzzing · Nausea · Excessive sweating · Dry mouth · Bodily lightness · Breathing alteration · Involuntary body movements · Sexual arousal enhancement · Bodily heaviness · Headache · Yawning · Salivation · Increased urination · Abnormal heartbeat · Nystagmus (eye wobbles) · Trembling · Motor control enhancement · Vomiting · Seizure threshold reduction · Bodily dissociation
Aesthetic enhancement · Cognitive flexibility · Introspection enhancement · Openness enhancement · Thought connectivity · Cognitive euphoria · Immersion enhancement · Increased nature relatedness · Multiple thought streams · Creativity enhancement · Thought acceleration · Thought loops · Memory fragmentation · Synchronicity · Analysis enhancement · Humor enhancement · Memory suppression · Cognitive fatigue · Cognitive impairment · Focus suppression · Information processing enhancement · Motivation enhancement · Focus enhancement · Language enhancement · Confusion · Memory replays · Thought disorganization · Cognitive dysphoria · Delusions
Openness enhancement · Thought connectivity · Cognitive euphoria · Immersion enhancement · Increased nature relatedness · Multiple thought streams · Creativity enhancement · Thought acceleration · Thought loops · Memory fragmentation · Synchronicity · Analysis enhancement · Humor enhancement · Memory suppression · Cognitive fatigue · Cognitive impairment · Focus suppression · Information processing enhancement · Motivation enhancement · Focus enhancement · Language enhancement · Confusion · Memory replays · Thought disorganization · Cognitive dysphoria
Simultaneous emotions · Catharsis · Anxiety · Anxiety suppression · Dysphoria
Dysphoria
Depersonalization · Disinhibition · Sociability enhancement · Communication enhancement · Flow state · Compulsive behavior reduction · Ego inflation · Boundary dissolution · Ego dissolution · Identity alteration
Flow state · Compulsive behavior reduction · Ego inflation · Boundary dissolution · Ego dissolution · Identity alteration
Time cessation
Transpersonal memory access · Transpersonal visions · Death-rebirth sequence · Entity contact
Timeline
First alerts appear as subtle mood shift and mild stimulation. A slight brightening of colors or heightened sensory awareness signals absorption.
Effects build steadily with increasing visual and cognitive shifts. Body load emerges — mild cramping and stimulation. Euphoria begins to develop.
Maximum intensity: visual drifting, color enhancement, cognitive euphoria, and tactile enhancement are at their strongest. Thought acceleration and pattern recognition are prominent. Less cognitive confusion than LSD at equivalent subjective intensity.
Effects recede relatively quickly compared to other lysergamides. Visuals fade first, followed by gradual normalization of cognition. Residual stimulation and mild euphoria may persist.
Subtle mood elevation, mild stimulation, and enhanced appreciation for sensory input may continue for several hours. Sleep may be delayed by residual stimulation.
⚠ Do not drive or operate machinery for at least 8 hours after ingestion, as residual cognitive and perceptual effects may persist below conscious awareness.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Low
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose has been established for MiPLA, and no human fatalities have been reported. By class inference from LSD — which has a high therapeutic index with no confirmed deaths from pharmacological toxicity alone — MiPLA is expected to have low acute toxicity at typical doses.
Heart and circulation
Chronic use of ergoline-class drugs can cause heart valve thickening by stimulating a specific receptor subtype. Rouaud and colleagues found structural similarities between psychedelic compounds and known heart-toxic agents, raising concern for repeated-exposure scenarios such as microdosing.[16] No clinical cases of LSD-induced valve damage have been reported, and no MiPLA-specific heart data exist.safety citation needed
Psychological risks
No controlled studies of MiPLA's psychological risk profile exist. Risks are inferred from the lysergamide class:
- Acute distress: anxiety, panic, paranoia, and thought loops can occur with any serotonergic psychedelic, particularly in uncontrolled settings or at unexpectedly high doses.
- Persistent visual disturbances (HPPD): Some people develop ongoing visual disturbances after psychedelic use — tracers, patterns, or halos persisting for weeks or longer. This has been documented even after a single exposure.[17][18] Flashback phenomena have also been documented in controlled LSD studies.[19] No MiPLA-specific cases have been reported.
- Psychosis: serotonergic psychedelics can trigger persistent psychotic episodes in people with a predisposition to psychotic disorders. No MiPLA-specific data exist.
Tolerance and dependence
MiPLA produces rapid tolerance — serotonin receptors in the frontal cortex downregulate quickly after exposure, with tolerance observable after a single dose.[6] Cross-tolerance exists with other serotonergic psychedelics, and full reset takes approximately 14 days.[14]
Classical serotonergic psychedelics, including MiPLA, produce no physical dependence and no withdrawal. Rapid tolerance acts as a natural brake on repeated use.
Drug interactions
Serotonin syndrome risk
Tramadol combined with MiPLA can overload the serotonin system — producing muscle rigidity, dangerous elevation of body temperature, and cardiovascular instability. Tramadol has been involved in fatal reactions when combined with other serotonergic agents.[20] This interaction is dangerous.
Monoamine oxidase inhibitors (MAOIs) prevent serotonin from breaking down, dramatically amplifying the effects of any serotonergic drug. Combining MiPLA with an MAOI creates severe risk of the same dangerous overheating and seizure response.[20] This interaction is dangerous.
SSRIs and SNRIs typically reduce psychedelic effects through receptor adaptation. Combining them with a direct serotonin agonist carries theoretical risk of serotonin overload, though the clinical significance is less established than for MAOI combinations.
Analytical misidentification
Standard reagent tests cannot distinguish MiPLA from LSD — both produce identical color reactions because both contain the same structural group.[2][21] Drug-checking services have misidentified MiPLA as LSD in proficiency testing.[5] Laboratory-grade analysis (GC-MS or LC-MS/MS) is required for reliable differentiation.
Contraindications
No substance-specific contraindication data exist. By class pharmacology of serotonergic psychedelics:
- Psychotic disorders (absolute): Personal or first-degree family history of schizophrenia or other psychotic disorders.
- Bipolar disorder (absolute): Risk of manic episode precipitation.
- Lithium (absolute): Documented risk of seizures and severe adverse reactions when combined with serotonergic psychedelics.safety citation needed
- Heart conditions (relative): stimulant-like cardiovascular effects may worsen pre-existing conditions.
- Seizure disorders (relative): Psychedelics may lower the seizure threshold; no MiPLA-specific evidence.
- Pregnancy (absolute): No reproductive data exist; ergoline compounds have uterine-stimulating properties as a class.
Harm Reduction[edit]
Forms & Identification
MiPLA circulates exclusively on blotter paper. Standard reagent tests — Ehrlich and Hofmann — confirm the presence of an indole compound but cannot distinguish MiPLA from LSD, because both contain the same structural group that triggers the color reaction.[2] Laboratory analysis (GC-MS or LC-MS/MS) is the only reliable method for differentiation.[21]
This matters because MiPLA is approximately one-third to one-half as potent as LSD by weight.[1] Blotters sold as LSD that contain MiPLA produce weaker effects — potentially prompting redosing that could overshoot if a subsequent blotter contains actual LSD. Drug-checking services have confirmed this confusion is common.[5]
Guidelines
- Test all blotter material with an Ehrlich reagent to confirm the presence of an indole compound. A positive result does not distinguish MiPLA from LSD.
- Start with a low dose and wait at least 90 minutes before assessing whether effects have fully developed.
- Keep the environment calm, warm, and physically safe. Remove hazards. Have water and light food available.
- Have a sober companion present, especially for anyone unfamiliar with the substance.
- Avoid mixing with other substances, particularly alcohol and cannabis.
- Plan for the full duration plus a wind-down period — clear the rest of the day.
Set & Setting
MiPLA's compressed duration means environmental shifts carry proportionally more weight than with longer-acting lysergamides. Choose a setting that will remain comfortable for the full arc — a familiar indoor space or safe outdoor environment with access to shelter.
A trusted, sober companion is strongly recommended, particularly at higher doses or for anyone unfamiliar with the lysergamide class. Enter the experience in a stable mental state, without unresolved acute stressors.
Aftercare & integration. MiPLA's shorter duration means the comedown is typically gentler than after LSD. Journaling within 24 hours captures specific images, feelings, or insights before they fade.
Difficulty sleeping is less common than after LSD. Eat a nourishing meal and allow the body to rest naturally. If the experience raised difficult emotions, seek conversation with someone trusted. If distressing perceptual changes, persistent anxiety, or depersonalization continue beyond 48 hours, consult a mental health professional.
Recovery & Support
Classical psychedelics including MiPLA do not produce physical dependence or withdrawal. Psychological patterns of overuse can develop — using psychedelics as avoidance or escape rather than occasional exploration. If psychedelic use is becoming compulsive or interfering with daily functioning, professional support is appropriate. The Fireside Project (62-FIRESIDE / 623-473-7433) offers free peer support for psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most difficult moments on MiPLA resolve without medical intervention. Seek immediate help if someone shows signs of self-harm risk, complete disconnection from reality, seizures, or sustained chest pain.
Immediate steps:
- 1. Stay with the person. Speak calmly and simply.
- 2. Move them to a quiet, low-stimulation environment if possible.
- 3. Do not restrain them unless they are in immediate physical danger.
- 4. If symptoms are purely psychological (panic, confusion, thought loops), grounding techniques — naming objects in the room, gentle physical contact if welcomed — can help.
- 5. Call emergency services if the person is unresponsive, seizing, or expressing intent to harm themselves.
What to tell the dispatcher: Name the substance (MiPLA or lysergamide), the approximate amount, when it was taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
MiPLA is not explicitly named in controlled substance schedules in most countries but may be captured by structural analog legislation or blanket psychoactive substance bans.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not explicitly scheduled | Not listed in Schedule I. As a structural isomer of LSD (Schedule I), the Federal Analogue Act (21 U.S.C. § 813) may treat it as Schedule I when intended for human consumption. No court precedent specific to MiPLA exists. |
| United Kingdom | Controlled (blanket ban) | Covered under the Psychoactive Substances Act 2016, which prohibits production, supply, and possession with intent to supply of any psychoactive substance not specifically exempted. |
| Germany | Controlled (NpSG) | Covered under the Neue-psychoaktive-Stoffe-Gesetz since July 18, 2019. Trading, supply, and import for market are criminal offences; possession is prohibited but not penalized. |
| France | Controlled | Classified as illegal.citation needed |
| Switzerland | Likely controlled | Potentially covered as a lysergic acid derivative under Verzeichnis E, point 263. Explicit scheduling status unconfirmed. |
| Canada | Not controlled | Not listed in the Controlled Drugs and Substances Act schedules as of 2025. |
| Australia | Likely controlled | Not explicitly scheduled; likely captured under analogue provisions given ergoline structural class. Status unconfirmed. |
Analogue act considerations
As a structural isomer of LSD with confirmed LSD-like pharmacological activity,[1] MiPLA likely satisfies the Federal Analogue Act's criteria of being "substantially similar" in structure and effect. The Act requires case-by-case judicial determination, and no prosecution specifically involving MiPLA has been reported.
Legal status changes frequently and varies by jurisdiction. This information does not constitute legal advice.
references
- [1]
- [2]
- [3]
- [4] ^abTanaka R, Kawamura M, Hakamatsuka T, Kikura-Hanajiri R (2020) Identification of LSD Derivatives, 1cP-LSD, MIPLA and 1B-LSD in Illegal Products as Paper Sheet — Yakugaku Zasshi doi:10.1248/yakushi.20-00124
- [5] ^abcdBalcaen M, Ventura M, Gil C, Luf A, Martins D, Cunha M, Togel-Lins K, Wolf D, Blanckaert P, Deconinck E (2023) Challenges in Drug Surveillance: Strengthening the Analysis of New Psychoactive Substances by Harmonizing Drug Checking Services in Proficiency Testing — International Journal of Environmental Research and Public Health doi:10.3390/ijerph20054628
- [6] ^abde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170